Cartesian Therapeutics (RNAC) Tops Q2 EPS by 50c
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.50. Revenue for the quarter came in at $300 thousand.
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
- Simulations Plus (SLP) Tops Q3 EPS by 7c
- CCC Intelligent Solutions explores potential sale with Morgan Stanley - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
